AFP and hepatocellular carcinoma: Of the drugs that have been approved in Japan as molecular targeted agents for unresectable HCC, regorafenib and ramucirumab have shown efficacy in phase III trials as a second-line chemotherapy after sorafenib and regorafenib is often administered because ramucirumab is indicated only for patients with serum AFP values of 400 ng/mL or higher.